Skip to main content
Premium Trial:

Request an Annual Quote

Precision System Science, Hitachi Ink Alliance

NEW YORK (GenomeWeb) – Precision System Science recently announced a business alliance with Hitachi High-Technologies that it said will "enable the firm to further strengthen its business platform as an innovative biotechnology company."

Under the terms of the deal, PSS will supply to Hitachi its nucleic acid isolation system, fully automated diagnostic instruments, and reagents. In return, Hitachi will provide to PSS technology, production, sales network, and manpower.

PSS has allotted about 2.3 million shares of its common stock, or 10 percent of its total outstanding shares, to Hitachi, which will also have a representative on PSS' board.

Headquartered in Chiba, Japan, PSS develops instruments for the in vitro diagnostics field. In addition to its fully automated nucleic acid isolation system, the firm offers a magnetic beads-based multipurpose open platform system, and a microarray sample preparation instrument, according to its website.

A PSS spokesman said that a goal of the deal with Hitachi is to develop high-throughput tools for the diagnostics space.

In fiscal 2016, PSS posted ¥4.46 billion ($40.0 million) in revenues, it said. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.